EMA Authorised: Fymskina (ustekinumab) — Formycon AG

View source ↗

Summary

The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Fymskina (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease;Psoriasis;Arthritis, Psoriatic. MAH: Formycon AG. Decision date: 23/02/2026